Xcelerate, Inc. Announces Commencement of the Nationalization Process for its PCT International Patent Applications
Xcelerate, Inc. (OTCQB: XCRT) has announced the start of the nationalization process for two PCT international patent applications. These patents introduce a revolutionary 'first-person view' to surgical procedures by integrating cameras into surgical tools. This innovation aims to enhance surgical precision, speed, and reduce incision size.
The technology also incorporates surgical site illumination and targeting marker projection. CEO Mike O'Shea emphasized the company's dual focus on uplisting to Nasdaq and nationalizing their medical device patents. Xcelerate plans to utilize the European Unitary Patent Application Process, covering 17 EU member states, including Germany, France, and Italy. Additional markets targeted include China, Ireland, Japan, and Mexico.
Xcelerate, Inc. (OTCQB: XCRT) ha annunciato l'inizio del processo di nazionalizzazione per due domande di brevetto internazionale PCT. Questi brevetti introducono una rivoluzionaria 'visione in prima persona' nelle procedure chirurgiche integrando telecamere negli strumenti chirurgici. Questa innovazione mira a migliorare la precisione chirurgica, la velocità e ridurre le dimensioni delle incisioni.
La tecnologia include anche l'illuminazione del sito chirurgico e la proiezione di marker per il targeting. Il CEO Mike O'Shea ha sottolineato il doppio obiettivo dell'azienda di passare al Nasdaq e nazionalizzare i propri brevetti per dispositivi medici. Xcelerate prevede di utilizzare il Processo di Domanda di Brevetto Unitario Europeo, che copre 17 stati membri dell'UE, tra cui Germania, Francia e Italia. Altri mercati target includono Cina, Irlanda, Giappone e Messico.
Xcelerate, Inc. (OTCQB: XCRT) ha anunciado el inicio del proceso de nacionalización para dos solicitudes de patente internacional PCT. Estas patentes introducen una revolucionaria 'visión en primera persona' en los procedimientos quirúrgicos al integrar cámaras en las herramientas quirúrgicas. Esta innovación tiene como objetivo mejorar la precisión quirúrgica, la velocidad y reducir el tamaño de las incisiones.
La tecnología también incorpora iluminación del sitio quirúrgico y proyección de marcadores de destino. El CEO Mike O'Shea enfatizó el enfoque dual de la compañía en listarse en el Nasdaq y nacionalizar sus patentes de dispositivos médicos. Xcelerate planea utilizar el Proceso de Solicitud de Patente Unitaria Europea, que cubre 17 estados miembros de la UE, incluidos Alemania, Francia e Italia. Los mercados adicionales a los que se dirige incluyen China, Irlanda, Japón y México.
Xcelerate, Inc. (OTCQB: XCRT)는 두 개의 PCT 국제 특허 신청에 대한 국유화 절차의 시작을 발표했습니다. 이 특허는 수술 도구에 카메라를 통합하여 수술 절차에 혁신적인 '1인칭 시점'을 도입합니다. 이 혁신은 수술의 정밀도, 속도를 향상시키고 절개 크기를 줄이는 것을 목표로 합니다.
이 기술은 또한 수술 부위 조명 및 타겟 마커 프로젝션을 포함합니다. CEO Mike O'Shea는 회사의 나스닥 상장과 의료 기기 특허의 국유화에 대한 이중 초점을 강조했습니다. Xcelerate는 독일, 프랑스, 이탈리아 등 17개 EU 회원국을 포함한 유럽 단일 특허 신청 프로세스를 활용할 계획입니다. 추가로 타겟팅하는 시장은 중국, 아일랜드, 일본 및 멕시코입니다.
Xcelerate, Inc. (OTCQB: XCRT) a annoncé le début du processus de nationalisation pour deux demandes de brevet international PCT. Ces brevets introduisent une 'vue à la première personne' révolutionnaire dans les procédures chirurgicales en intégrant des caméras dans les outils chirurgicaux. Cette innovation vise à améliorer la précision chirurgicale, la rapidité et à réduire la taille des incisions.
La technologie intègre également l'éclairage du site chirurgical et la projection de marqueurs de ciblage. Le PDG Mike O'Shea a souligné l'objectif double de l'entreprise de s'introduire au Nasdaq et de nationaliser ses brevets de dispositifs médicaux. Xcelerate prévoit d'utiliser le processus de demande de brevet unitaire européen, couvrant 17 États membres de l'UE, dont l'Allemagne, la France et l'Italie. D'autres marchés ciblés incluent la Chine, l'Irlande, le Japon et le Mexique.
Xcelerate, Inc. (OTCQB: XCRT) hat den Beginn des Nationalisierungsprozesses für zwei PCT internationale Patentanmeldungen bekannt gegeben. Diese Patente führen eine revolutionäre 'Ich-Perspektive' in chirurgische Verfahren ein, indem Kameras in chirurgische Werkzeuge integriert werden. Diese Innovation zielt darauf ab, die chirurgische Präzision, Geschwindigkeit zu verbessern und die Schnittgröße zu reduzieren.
Die Technologie umfasst auch die Beleuchtung des chirurgischen Bereichs und die Projektion von Zielmarkierungen. CEO Mike O'Shea betonte den doppelten Fokus des Unternehmens auf den Wechsel zum Nasdaq und die Nationalisierung ihrer Medizingerätepatente. Xcelerate plant, das Verfahren zur Antragsstellung für europäische Einheitspatente zu nutzen, das 17 EU-Mitgliedstaaten umfasst, darunter Deutschland, Frankreich und Italien. Weitere anvisierte Märkte sind China, Irland, Japan und Mexiko.
- Commencement of nationalization process for two PCT international patent applications
- Innovative 'first-person view' technology for surgical procedures
- Potential to increase surgical precision and speed while reducing incision size
- Plans to uplist common stock to Nasdaq
- Utilization of European Unitary Patent Application Process covering 17 EU member states
- None.
MAULDIN, SC / ACCESSWIRE / August 22, 2024 / Xcelerate, Inc. (OTCQB:"XCRT") today announced the commencement of the nationalization process for its two PCT international patent applications, PCT/US2023/015755 and PCT/US2023/016194. These international patents correspond to the US utility patent applications US 18/187,352 and US 18/189,441 filed with the United States Patent and Trademark Office (USPTO). The key innovation provided by these patents is the introduction of a new "first-person view" to the surgical theatre. This technology integrates cameras directly into surgical tools in order to allow the surgeon to follow and perform the procedure from his tool's perspective. We believe this introduction of the "first-person view" has the potential to significantly boost the precision and speed of a surgical procedure, as well as reducing the size of the surgical site. As an additional potential benefit, the technology integrates surgical site illumination and allows for the projection of targeting markers.
Mike O'Shea, Xcelerate's CEO stated "In addition to our efforts to uplist our common stock for listing on Nasdaq, we are also focusing on the nationalization of our medical device patents. The nationalization of these patents is a significant advancement in Xcelerate's mission to leverage non-medical engineering advancements and intellectual property for clinical and medical care. Mr. O'Shea continued by stating "We are looking forward to using the European Unitary Patent Application Process for the first time. Unitary Patent Applications have been possible since June 2023 and allow filers to cover 17 member states of the European Union (EU) with a single application. This includes the EU's three largest economies: Germany, France, and Italy. Other markets which will be covered include China, Ireland, Japan, and Mexico."
ABOUT XCELERATE INC.
In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. In 2022, we expanded this business plan to include the marketing and sale of over-the-counter healthcare products. For more information visit the Company's website at www.xcelerate.global.
SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.
For Additional Information Contact:
Michael O'Shea, CEO
Xcelerate, Inc.
mike@xcelerate.global
854-900-2020
SOURCE: Xcelerate
View the original press release on accesswire.com
FAQ
What new technology has Xcelerate (XCRT) announced for surgical procedures?
How many PCT international patent applications is Xcelerate (XCRT) nationalizing?
What are the potential benefits of Xcelerate's (XCRT) new surgical technology?
Which major markets is Xcelerate (XCRT) targeting for its patent applications?
What is Xcelerate's (XCRT) plan for its stock listing?
